## 13<sup>th</sup> EIP Open Symposium

Summary - Outlook April 27<sup>th</sup> 2022 Daniel Kramer



# "Prediction"

- Impact of Covid-19 on prediction tools
  - Since 2021
    - Drop of CD8+ cells
    - Increase of CD4+ cells
    - Increase of HLA-DR positive cells
    - Increase of B-cells (towards end of 2021)
  - Impact on human immunogenicity to be seen
- Machine learning methods is a promising approach to improve immunogenicity
- Certain HLA alleles are associated with a higher likelihood for ADA responses
  - HLA-DQA1\*05 is associated with immunogenicity to anti-TNFs in Croh's disease

FIP

- Should we introduce HLA typing in our clinical trials?

#### Immunogenicity Assay Strategies

- EIP initiative to harmonize Immunogenicity Risk
  Assessment
- Risk assessment for gene and cellular therapies is presents some additional challenges compared to classical biotherapeutics
- Selection of positive controls is key for ADA validation results
- Cross-validation of ADA assays is an upcoming important topic
  - Chinese studies present a certain challenge
- Are singulets are way forward to minimize the burden for titrating confirmed positive ADA samples?



# **Critical Quality Attributes**

- The effect of infliximab on immunogenicity could be either due to
  - Deliver of a danger signal (e.g. TLR2) boosting a humoral immune response
  - Augmentation of presentation of (novel) T-cell epitopes
- The battery of assays to analyze particles in biologics is substantial
- Are non-natural (D-amino acids) a way to decrease immunogenicity
- For certolizumab pegol the PEG moiety seems to inhibit the uptake into antigen presenting cells thereby reducing immunogenicity



### **Clinical Relevance**

- Sometimes a dedicated Nab assay might not provide added value over a holistic ADA, PK, PD (& efficacy) evaluation (Emicizumab in hemophilia A)
- The VEGF levels might be a good indicator of neutralization of Bevacizumab

#### **Next EIP Meeting**

• Lisbon, April 24<sup>th</sup> - 26<sup>th</sup> 2023 (tbc)





### **Conference Report**

- EIP wishes to share the discussion at the meeting with a broader audience
  - Intention to publish a conference report
  - We will find ways to combine it with the report from last year
- Sophie Tourdot will reach out to each speaker to send a small abstract of their talks



• Join the EIP

–High class scientific discussions

-Training for singing ;-)

#### Thanks for joining and have a good trip back